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SNX-2112, a novel inhibitor of Hsp90 currently used as an anti-tumor drug, induces apoptosis in
multiple tumor cell lines. It destabilizes speciﬁc client proteins, but the molecular mechanism of
the apoptosis effect of SNX-2112 is poorly understood. Here, we analyzed the apoptotic effect of
SNX-2112 on human chronic myeloid leukemia (CML) K562 cells. Transcriptomic and proteomic
approaches further revealed that caspase signals originated from mitochondria dysfunction, medi-
ated by Akt signaling pathway inactivity. Additionally, SNX-2112 prolonged the survival time of
NOD/SCID mice inoculated with K562 tumor cells. Our results demonstrated the therapeutic poten-
tial of SNX-2112 against human CML.
Structured summary:
MINT-7033976: BAD (uniprotkb:Q92934) physically interacts (MI:0218) with Bcl2-Xl (uniprotkb:Q07817)
by anti bait coimmunoprecipitation (MI:0006)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction multi-step malignancy, and also with mutated oncogenic proteinsHsp90 (heat shock protein 90) is a molecular chaperone that
modulates the stability and/or transport of a diverse set of critical
cellular regulatory, metabolism, organization, and signaling pro-
teins [1]. It allows cancer cells to tolerate the many components
of dysregulated pathways in a transformation speciﬁc manner by
interacting with several client substrates, such as kinases, hormone
receptors and transcription factors directly involved in drivingchemical Societies. Published by E
ethoxygeldanmycin; DMSO,
FBS, fetal bovine serum; IEF,
RDX5, peroxiredoxin V; DLD,
zyme A hydratase 1; IDH3A,
yde dehydrogenase 2 family;
AP1, tumor necrosis factor-
oncogene homolog (avian)-
ipt.required for the transformed phenotype [2].
SNX-2112, a novel inhibitor of Hsp90, selectively binds to the
ATP pocket of Hsp90 and is more pharmacologically effective than
17-(allylamino)-17-demethoxygeldanmycin (17-AAG) [3]. Here,
we provide evidence that SNX-2112 can induce apoptosis in hu-
man chronic leukemia K562 cells. A series of assays revealed that
SNX-2112 not only degraded its client protein Bcr-Abl but also im-
paired mitochondria function resulting in K562 cells apoptosis.
Simultaneously, we found a possible mechanism related to Akt sig-
naling pathway inactivity. Furthermore, consecutive injection of
SNX-2112 prolonged the survival time of NOD/SCID mice inocu-
lated with K562 cells.2. Materials and methods
2.1. Reagents, antibodies and cells
SNX-2112 was made by our lab as described [4] with a pur-
ity > 98.0%. 17-AAG was from Alexis Biochemicals (San Diego,lsevier B.V. All rights reserved.
1860 L. Jin et al. / FEBS Letters 583 (2009) 1859–1866CA). SNX-2112 and 17-AAG stocks at 10 mmol/L dimethylsulfoxide
(DMSO) in solution were stored at 4 C and 20 C, respectively.
Antibodies against these proteins were purchased: caspase-3, 8,
9, PARP, p-Bad (Ser112), and Bcr-Abl protein (Cell Signaling, Bev-
erly, MA); cytochrome c, p-Akt(Thr308), Akt, Bad, Bcl-xL,14-3-3
(Epitomics, Burlingame, CA); Crkl, Grb2 and b-actin (Santa Cruz,
Santa Cruz, CA). Human chronic myeloid leukemia (CML) K562
cells (ATCC, Manassas, VA) were grown in RPMI-1640 with 10%
heat inactivated fetal bovine serum (FBS), and 100 U/ml of penicil-
lin and streptomycin.
2.2. MTT assay
2  105 K562 cells were seeded in a 96-well plate with various
concentrations of SNX-2112 for 72 h.
Then 20 ll of RPMI-1640 with 10% FBS and 5 mg/ml MTT were
added. The precipitated formazan was dissolved in 100 ll of
DMSO. Cell viability was assessed at optical density = 570 nm.
2.3. Assessment of apoptosis
Cells were washed in PBS and resuspended in 100 ll of incuba-
tion buffer containing Annexin V-FITC and PI. Samples were incu-
bated at RT for 10 min and analyzed by FACS.
2.4. Western blot
Cells were lysed in RIPA buffer and protein measured by Brad-
ford assay. Cell extracts were run on SDS–PAGE, blotted on PVDF
membranes, blocked with 5% non-fat milk, and probed with vari-
ous antibodies. Speciﬁc protein bands were visualized with ECL
chemiluminescence (Pierce, Rockford, IL) and imaged by
autoradiography.
2.5. Transcriptomic analysis
cRNA was prepared and hybridized to Affymetrix Human Gen-
ome U133 Plus 2.0 Array. Each microarray dataset was normalized
by Robust Multichip Averaging (RMA) method and correlation of
all signals intensity > 95%. Triplicate arrays were analyzed with
Welch t-test. Genes with P < 0.01 and a group mean difference
P1 or 61 were considered signiﬁcantly modulated and chosen
for analysis. Gene Ontology annotation terms were generated with
Pathway Studio version 5.0 software (Ariadne Genomis, Rockville,
MD). The Kyoto Encyclopedia of ResNet Mammalian database
was used as a search tool [5].
2.6. Proteomics analysis
Cells induced with 1 lM SNX-2112 for indicated time were har-
vested, rinsed, lysed for 30 min at 4 C, then centrifuged (12 000g,
4 C) for 15 min. Proteins in the lysates were measured by the
Bradford assay, then separated by isoelectric focusing (IEF) using
immobilized pH gradient (IPG) drystrips with pH range 3–10 on Et-
tan IPGphor 3 (General Electric Company, USA) with a voltage gra-
dient. Proteins were resolved in the 2nd dimension with SDS–PAGE
and 12.5% gels were stained with silver nitrate overnight. Gel
images were analyzed with Image Master 2D Platium 6.0. Peptide
mass spectra were obtained on an Applied Biosystem Sciex 4800
MALDI TOF/TOF mass spectrometer.
Data were acquired in a positive MS reﬂector using a CalMix5
standard for calibration (ABI4700 Calibration Mixture). The MS
and MS/MS spectra for each spot were combined and run on the
MASCOT search engine (V2.1, Matrix Science, UK) using GPS Ex-
plorer software (V3.6, Applied Biosystems). MASCOT protein
scores > 61 were statistically signiﬁcant (P < 0.05).2.7. Isolation of the cytosolic fraction
Isolation of the cytosolic fraction was performed at 4 C as de-
scribed [6]. Brieﬂy, cells were lysed in ice-cold sucrose buffer.
The lysate was centrifuged at 600g for 10 min to remove nuclei
and unbroken cells. Then, supernatant was spun at 14 000g for
15 min to eliminate mitochondria. The supernatant was centri-
fuged again at 100 000g for 1 h. The protein concentration of
the supernatant, representing the cytosolic fraction, was assayed
by the Bradford assay. Cytochrome c in the cytosolic fraction was
then analyzed by Western blot.
2.8. JC-1 for mitochondrial transmembrane potential study
5  105 cells were incubated with 10 lg/ml JC-1 for 30 min at
37 C, then washed with PBS and resuspended in 250 ll PBS.
Highly negative membrane potential in mitochondria produces
JC-1 red ﬂuorescence. Loss of mitochondrial transmembrane po-
tential results in green ﬂuorescence and loss of the red
ﬂuorescence.
2.9. Co-immunoprecipitation (co-IP)
Cells seeded for indicated time were lysed with IP buffer. Clar-
iﬁed cell lysates were incubated with antibodies against speciﬁc
proteins for 90 min at 4 C with gentle shaking, then absorbed to
protein G plus-agarose beads (Santa Cruz, Santa Cruz, CA). Beads
were extensively washed; the eluted complex was resuspended
in SDS sample buffer, and separated by 12.5% SDS–PAGE.
2.10. Surface antigen CD13 and CD33 analysis by ﬂow cytometry
Cells were suspended in PBS, stained for 30 min on ice with
anti-CD13-PE or CD33-PE and anti-glycophorin A-FITC antibodies
(Beckman Coulter, USA). FITC- or PE-labeled mouse IgG alone were
negative controls.
2.11. Animals and administration of SNX-2112
Six-eight weeks old NOD/SCID mice from Chinese Academy of
Medical Sciences (Beijing, China) were given commercial food,
water ad libitum, and housed at 23 ± 5 C and 55 ± 5% RH through
the experiment. Eight mice per group were inoculated by tail vein
with 107 K562 cells. SNX-2112 was dissolved in saline with 10%
DMSO; 17-AAG was dissolved in saline with 10% DMSO including
0.05% Tween-20 [7].
2.12. Statistical analysis
Data were evaluated by Welch t-test when only 2 value sets
were compared. One-way ANOVA followed by Dunnett’s test for
3 or more groups. Survival was analyzed using the Kaplan–Meier
log-rank test. Results are expressed as mean ± S.D. with signiﬁ-
cance at P < 0.05 or P < 0.01.3. Results and discussion
3.1. SNX-2112 induced apoptosis in human chronic leukemia K562
cells
We ﬁrst determined the cytotoxic concentration of SNX-2112
on K562 cells using MTT assays on cells treated with various con-
centrations of the drug for 72 h. SNX-2112 showed a dose-depen-
dent cytotoxic effect with IC50 = 0.92 lM (Fig. 1A). Then, we
evaluated the apoptotic effect by ﬂow cytometry of Annexin V-FITC
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positive control. The ratio of apoptotic cells increased from
10.6 ± 2.1% up to 75.8 ± 7.4% after exposure to SNX-2112 at 0.05–
10 lM, signiﬁcantly greater than with 17-AAG (Fig. 1B).
We next analyzed the effect of SNX-2112 on cleavage of caspase
family proteins to determine whether caspase activation contrib-
utes to SNX-2112-induced K562 cell apoptosis. The activation of
caspase-3, the major effector caspase, requires activation of initia-
tor caspases such as caspase-8 or -9 in response to pro-apoptotic
signaling [8]. The cleavage of PARP is a speciﬁc hallmark of acti-
vated caspase-3 [9,10]. Notably, we observed a substantial increase
in caspase-9 activity with SNX-2112 from 1 to 10 lM (Fig. 1C,
upper). Treatment with 0.1 and 0.05 lM of the agent, respectively,
also did not induce complete cleavage of caspase-9, indicating
early apoptosis in the cells. SNX-2112 also dose-dependently in-
duced pro-caspase-3 degradation (Fig. 1C, middle) which could
lead to caspase-3 activation. Intracellular pro-PARP also dose-
dependently decreased with a corresponding increase in cleavage
of the 116 to 89-kDa protein (Fig. 1C, bottom). At low dose of
0.1 lM, SNX-2112 did not activate pro-caspase-3 and PARP. Cas-
pase-8 is an upstream caspase that relays the death signal from
Fas receptor–ligand interactions to the downstream caspase-3
and processes pro-caspase-3 [11]. However, pro-caspase-8 was
not cleaved and its total level was unchanged (Fig. 1C), indicating
the FasL/Fas pathway may not be involved in SNX-2112 induced
apoptosis.
Therefore, SNX-2112 activated initiator caspase-9, which is clo-
sely coupled to pro-apoptotic signals. Once activated, caspase-9
activated downstream effector caspase-3, which in turn cleaved nu-
clear protein PARP. Based on these results, the treatment condition
with SNX-2112 at 1 lM was selected for the following analysis.
3.2. Apoptosis induced by SNX-2112 is related to mitochondria
dysfunction
The ﬁndings above indicated that SNX-2112 may trigger the
intrinsic mitochondrial pathway of apoptosis. In addition to energy
production, mitochondria are involved in many cellular processes
such as metabolism, signaling, cell growth and apoptosis [12,13].
Mitochondrial dysfunctions and cytochrome c release to the cytosol
are signiﬁcantly associated with caspase activation [14]. To provide
molecular evidence for mitochondrial dysfunction in response to
SNX-2112, we comprehensively proﬁled alterations in gene expres-
sion upon treatment. Prepared RNA from K562 cells treated with or
without 1 lM SNX-2112 for 48 h were hybridized to Affymetrix
Human Genome U133 Plus 2.0 Array chips. Randomly selected
genes from the microarray results were conﬁrmed by real-time
PCR (data not shown). In all, 229 genes accounting for 10.75% of to-
tal selectors were up-regulated or down-regulated compared with
control group. Among these, 136 and 93 genes have known and un-
known functions, respectively (Supplementary Tables 1 and 2). Of
the 136 known genes classiﬁed according to various functional
groups (Fig. 2A), 62.51% were related to various metabolism groups
and up- or down-regulated to different degrees, suggesting mito-
chondria dysfunction [15]. Except for coenzyme and prosthetic
group, numerous genes related to different substance metabolism
groups tended to down-regulate (Fig. 2B), indicating that the defect
in mitochondrial function can directly inhibit genes encoding
metabolism [16]. We attributed the few up-regulated genes
(Fig. 2B) to the dysfunction feedback signal, which may trigger
new compensatory metabolism gene synthesis.
We also found 7 proteins involved in mitochondrial dysfunction
from 55 identiﬁed proteins by proteomics analysis (Table 1). Per-
oxiredoxin V (PRDX5) is an antioxidant enzyme which neutralize
reactive oxygen species (ROS). Here, PRDX5 protein levels consis-
tently increased from 48 to 72 h, indicating that ROS producedby mitochondria can stimulate high levels of PRDX5 to further pro-
tect mitochondrial from impairment [17,18]. Over-expression of
dihydrolipoamide dehydrogenase (DLD), a pro-oxidant, can lead
to high ROS that induces mitochondrial damage [19,20]. In our
study, up-regulated DLD expression also provided indirect evi-
dence for mitochondrial dysfunction. Enoyl coenzyme A hydratase
1 (ECH1) was up-regulated > 2-fold, suggesting that high expres-
sion of ECH1 in mitochondria may stimulate the degradation of
medium-chain and short-chain, further disturbing fatty acid nor-
mal metabolism [21]. The human mitochondrial NAD(+)-speciﬁc
isocitrate dehydrogenase alpha subunit (IDH3A) is a NAD(+)-
dependent isocitrate dehydrogenase, catalyzing the regulated
rate-limiting step of the tricarboxylic acid cycle where the bulk
of ATP maintaining homeostasis is produced. Decrease of IDH3A
protein contributes to the reduction of ATP and down-regulation
of energy metabolism in mitochondria. We also found 2 down-reg-
ulated proteins involved in the mitochondrial electron transport:
aldehyde dehydrogenase 2 family (ALDH2) and NADH dehydroge-
nase ﬂavoprotein 2 (NDUFV2). Additionally, the NDUFV2 protein
dot reduced dramatically after treatment with SNX-2112 for
48 h. Reduced proteins participating in respiratory chain transport
can directly impair the electron transport in the mitochondrial in-
ner membrane. The latter can increase ROS and induce apoptosis
[22]. Finally, the tumor necrosis factor-associated protein 1
(TRAP1) also decreased >2 fold in our 2-D analysis. TRAP1 is a
mitochondrial heat shock protein, which can help its client pro-
teins fold correctly in mitochondria. Its high protein levels interfere
with caspase-3 activation and protect cells from oxidative stress
[23]. Our results conﬁrmed the above conclusion and indicated
that TRAP1 may be an indirect effector target of SNX-2112. In addi-
tion, except DLD and ALDH2, the expression of the other 5 proteins
corresponded to the changes on mRNA transcript expression.
In mitochondria, cytochrome c is required as an electron carrier
during oxidative phosphorylation. The electron transport mediated
by cytochrome c generates a proton gradient across the inner mito-
chondrial membrane required to maintain potential DW. Thus, the
release of cytochrome c from the electron transport chain is ex-
pected to impair the electron ﬂow and cause a decrease in DW.
Simultaneously, cytochrome c is released into the cytosol and acti-
vates pro-caspase-9 by binding apaf-1 [24,25]. Here, SNX-2112
(1 lM) induced the time-dependent release of mitochondrial cyto-
chrome c into the cytosol of K562 cells (Fig. 2C). Compared to un-
treated control, cytochrome c was visible at 12 h and fully
developed at 24 h. Furthermore, we used the potential sensitive
dyes JC-1 to study the mitochondrial DW. After SNX-2112 treat-
ment for 24 h,DW decreased in a time-dependent manner, demon-
strating a disruption of the DW during K562 apoptosis (Fig. 2D).
3.3. SNX-2112 caused Bad activation and the association of Bad and
Bcl-xL mediated by Akt signaling pathway
We thus studied transduction signals leading to mitochondria
dysfunction using a global proteomics approach to identify v-crk
sarcoma virus CT10 oncogene homolog (avian)-like (Crkl) and
growth factor receptor bound protein 2 (Grb2), 2 common up-
stream cell signaling proteins. Both Crkl and Grb2 proteins were re-
duced in Western blots after 48 h of SNX-2112 treatment, in
agreement with spot intensities from the 2-DE gels (Fig. 3A). Crkl
and Grb2 are known as adaptor proteins in p210Bcr-Abl complexes
also including Bcr-Abl itself [26,27], one of Hsp90 clients that can be
degraded by Hsp90 inhibitor [28,29]. Here, we found SNX-2112
could lower expression of Bcr-Abl to almost undetectable levels
(Fig. 3B). We speculate that SNX-2112 led to degradation of Bcr-
Abl and decomposition of p210Bcr-Abl complexes to further
down-regulate levels of Crkl and Grb2. Currently, we are investigat-
ing the underlying mechanisms.
Fig. 1. SNX-2112 induced apoptosis in K562 cells. (A) MTT assay of cytotoxicity in K562 cells cultured for 72 h with various doses of SNX-2112. Data are means ± S.D. of 3
repeats. *P < 0.05 and **P < 0.01, compared to untreated control. (B) Evaluation of apoptosis by Annexin V-FITC and PI binding assay after SNX-2112 treatment. n = 3
independent experiments. Data are means ± S.D. of 3 repeats. *P < 0.05 and **P < 0.01, compared to untreated control. (C) SNX-2112 effect on apoptosis-related proteins
expression. Fifty micrograms of whole-cell lysate of K562 cells treated with indicated concentration for 72 h for detection of pro-caspase-3, 8, 9 and PARP by Western blot. b-
Actin was a loading control. n = 3 independent experiments.
1862 L. Jin et al. / FEBS Letters 583 (2009) 1859–1866Crkl and Grb2 are signal molecules that participate together in
Akt signaling transduction [30,31]. As expected, 1 lM SNX-2112
caused signiﬁcant Akt dephosphorylation after 12 h of treatment
(Fig. 3C), while the Akt protein level was not affected by SNX-
2112. Additionally, our results suggested Akt signaling was much
more rapid compared to Crkl and Grb2 reduction, which partlydue to Bcr-Abl kinase degradation lead to the two adaptor proteins
inactivate the function such as SH2 and SH3 domains binding Akt
substrate and reduce phosphorylation of its target Akt, ﬁnally the
dysfunction effect served as a feed-back resulted in their self-
down-regulation [26,32]. Then, co-IP and Western blots were used
to analyze the interaction between Bcl-xL and Bad whose phos-
Fig. 2. Mitochondria dysfunction analyzed by a series of assays. (A) Functional classiﬁcation of mitochondrial genes from SNX-2112 treated K562 cells. (B) Percentage
summary of changes on the functional genes grouping related to mitochondrial metabolism. (C) Western blot of cytochrome c release in cytosol with treatment of K562 cells
with 1 lM SNX-2112. b-Actin was a loading control. Experiment repeated 3 times. (D) Representative ﬂow cytometric analyses of mitochondrial membrane potential using
JC-1. The shift of JC-1 ﬂuorescence from orange (FL2-A) to green (FL1-A) indicates a collapse of mitochondrial membrane potential. The % of cells with low mitochondrial
membrane potential was measured. Values are mean ± S.D. of 3 repeats. **P < 0.01, compared to untreated group.
L. Jin et al. / FEBS Letters 583 (2009) 1859–1866 1863phorylation is controlled by Akt pathway [33]. Here, phosphoryla-
tion of Bad was signiﬁcantly down-regulated after 12 h of SNX-
2112 treatment while total Bad protein levels did not change
(Fig. 3D). Moreover, SNX-2112 induced the dissociation of Bad
from 14-3-3 and more Bcl-xL was observed to interact with Bad,
accordingly (Fig. 3D).
3.4. SNX-2112 effect on survival time of NOD/SCID mice inoculated
with K562 cells
Finally, we tested the effect of SNX-2112 on survival of NOD/
SCID mice inoculated with K562 cells. The mice were given 107Table 1
Up- and down-regulated proteins related with mitochondrial function identiﬁed by prote
Protein name Accession number Sequence coverage (%) PI/Mr (Da)
PRDX5 IPI00759663 11 6.73/1702
ECH1 IPI00011416 26 8.16/3579
DLD IPI00015911 19 7.59/5411
IDH3A IPI00374151 10 5.84/3136
TRAP1 IPI00030275 23 7.21/5718
ALDH2 IPI00216805 48 5.79/5668
NDUFV2 IPI00291328 15 8.22/2737K562 cells in the tail vein to mimic human chronic leukemia inva-
sion [34]. Three randomized groups included: SNX-2112, 17-AAG
and control. We analyzed the expression of 2 signiﬁcant surface
antigens, CD13+ and CD33+, on myeloid leukemia K562 by FACS.
On day 5, >1% CD13+ and >1.5% CD33+were detected inmice periph-
eral blood, indicating that numerous human K562 cells had en-
grafted and proliferated in the mice. The mice were then treated
with 6 mg/kg SNX-2112 by tail vain injection from days 5–9 and
days 12–16. At the same time, 12 mg/kg 17-AAGwas injected IP into
another group. Untreated mice inoculated with K562 cells died of
diffuse leukemia while there was obvious lower expression of
CD13+ and CD33+ in SNX-2112 group vs. control group (Fig. 4A). Sur-omics analysis.
Fold change Function
48 h 72 h
0 12.7" 10.9" Oxidoreductase activity
3 2.1" 3.3" Fat acid metabolism
6 2.2" 2.8" Oxidoreductase activity
1 2.5; 3.1; Carbohydrate metabolic process
4 2.6; 2.1; Mitochondrial HSP90 protein against apoptosis
8 2.2; 2.4; Mitochondrial electron transport
4 >100; Mitochondrial electron transport
Fig. 3. SNX-2112 caused Bad activation and the association of Bad and Bcl-xL mediated by Akt signaling pathway. (A) Crkl and Grb2 protein analysis after SNX-2112
treatment of cells for indicated time. Left, Western blot detecting Crkl and Grb2 protein and normalized on bar graph with b-actin. Results are mean ± S.D. of 3 repeats. Right,
Detailed alterations of Crkl and Grb2 identiﬁed by 2-DE. (B) Western blot of Bcr-Abl protein of cells treated with of 1 lM SNX-2112. Experiment repeated 3 times. (C)
Expression of phosph-Akt and Akt in induced cells from 0 to 72 h, and normalized by b-actin in bar graph. Results are mean ± S.D. of 3 repeats. (D) Co-IP and Western blot
were used to test interactions between Bad and Bcl-xL in apoptosis. Cell lysates were incubated with anti-Bad antibody. b-Actin was a loading control. The histogram
represents 3 separate experiments. *P < 0.05 and **P < 0.01, compared with untreated cells.
1864 L. Jin et al. / FEBS Letters 583 (2009) 1859–1866vival time of all SNX-2112 treated mice was longer than that of un-
treated mice (P < 0.01), ranging 47 to >80 days (Fig. 4B). Untreated
mice had the shortest survival time of 30–53 days. Survival time
of 17-AAG treated mice was from 39 to 66 days.In conclusion, SNX-2112, a novel Hsp90 inhibitor, depleted Bcr-
Abl client protein and induced apoptosis in human CML cells
though mitochondria dysfunction mediated by Akt signaling path-
way. SNX-2112 clearly has anti-K562 activity in the small animal
Fig. 4. SNX-2112 showed therapeutic effect on NOD/SCID mice inoculated with K562 cells. (A) CD13 and CD33 surface antigen analysis by ﬂow cytometry. The histogram
represents at least 3 separate experiments. **P < 0.01, compared to untreated cell. (B) SNX-2112 treatment prolonged survival of NOD/SCID mice inoculated with K562 cells.
Survival study was analyzed with the Kaplan–Meier log-rank test.
L. Jin et al. / FEBS Letters 583 (2009) 1859–1866 1865model, suggesting this agent may have therapeutic potential
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